PTC Therapeutics | PTCT - Equity Capital And Reserves


PTC Therapeutics reported $-155.76M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Alnylam Pharmaceuticals USD 233.89M 16.7M Sep/2025
Amgen USD 9.62B 2.19B Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Cytokinetics USD -521.12M 216.32M Sep/2025
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Gilead Sciences USD 21.46B 1.78B Sep/2025
Incyte USD 4.65B 480.29M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Ironwood Pharmaceuticals USD -264.16M 44M Sep/2025
Novartis USD 44.75B 2.7B Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -155.76M 50.79M Sep/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
TG Therapeutics USD 607.22M 330.79M Sep/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 17.32B 143.4M Sep/2025
Xencor USD 625.32M 4.96M Sep/2025